Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Summary

This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.

Timeline

Start

2017-02-06

Primary completion

2018-09-10

Completion

2018-09-25

Outcome

Met primary endpoint

registry analysis (superiority test); Liraglutide 3.0 mg vs Placebo; p < .0001; Treatment difference -4.32 (95% CI -5.48 to -3.16); ANCOVA NCT02963922 ↗

registry analysis (superiority test); Liraglutide 3.0 mg vs Placebo; p <.0001; Odds Ratio (OR) 3.41 (95% CI 2.19 to 5.31); Regression, Logistic NCT02963922 ↗

Publications

• Results Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 May;43(5):1085-1093. doi: 10.2337/dc19-1745. Epub 2020 Mar 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	3 mg	Subcutaneous

Indications